Sudden Ascent: Is Recursion Pharmaceuticals NVIDIA’s AI Favorite?
NVIDIA's continued investment in Recursion Pharmaceuticals strengthens the view that Recursion is a favored investment within ...
Cathie Wood Explains Why She Likes Recursion Pharmaceuticals, Inc. (RXRX)
We recently published a list of the Top 10 AI Stocks Buzzing on Latest News. In this article, we are going to take a look at ...
25 Top AI Stocks That Could Boost Your Portfolio
Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and ...
Why Recursion Pharmaceuticals, Inc. (RXRX) Soared Last Week
We recently compiled a list of the Last Week’s Top 10 Stocks Post Double-Digit Gains. In this article, we are going to take a ...
SoftBank adds to shares in VTEX, YMM, cuts NMRA and exits DASH, among other moves
The Japanese investment holding company SoftBank Group ( OTCPK:SFTBY) purchased two new stakes: 20.45M shares in Pacific Biosciences of California ( PACB ), and 14.66M shares in Recursion ...
Recursion Pharmaceuticals (RXRX) Laps the Stock Market: Here's Why
In the most recent trading session, Recursion Pharmaceuticals (RXRX) closed at $8.50, indicating a +1.92% shift from the previous trading day.
Recursion: CDK7 Inhibitor Differentiation Is Initially Paying Off
Recursion is advancing REC-617, a promising reversible, non-covalent CDK7 inhibitor, showing potential in treating advanced solid tumors with positive interim phase 1 data. Read more here.
Recursion Pharmaceuticals files automatic mixed securities shelf
EST Recursion Pharmaceuticals (RXRX) files automatic mixed securities shelfMaximize Your Portfolio with Data Driven Insights:Leverage the ...
Zacks.com on MSN10d
Recursion Pharmaceuticals (RXRX) Exceeds Market Returns: Some Facts to Consider
In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $7.66, marking a +0.13% move from the previous day. The stock outpaced the S&P 500's daily gain of 0.03%. Elsewhere, the Dow ...